{"id":3690,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/amprenavir-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"amprenavir-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/amprenavir-txt\/","title":{"rendered":"Amprenavir.txt"},"content":{"rendered":"

Amprenavir<\/h1>\n

CLINICAL USE <\/H3>
\nProtease inhibitor:
\nHIV infection, in combination with other <\/p>\n

antiretroviral drugs
\n

DOSE IN NORMAL RENAL FUNCTION <\/H3>
\nCapsules:<\/p>\n
  • >50 kg: 1.2 g, twice a day\n
  • <50 kg: 20 mg\/kg, twice a day; maximum\n

    2.4 g daily<\/p>\n

  • With ritonavir 100 mg, twice a day:
    \n>50 kg: 600 mg, twice a day<\/p>\n

    Oral solution: 17 mg\/kg every 8 hours;
    \nmaximum 2.8 g daily
    \n

    PHARMACOKINETICS <\/H3>
    \n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n505.6\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n90\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n<3\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \n6\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n7.1\u201310.6\/Unchanged
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
    \n
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nDose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nNot dialysed. Dose as in normal renal function
    \n
  • HDF\/high flux &nbsp :
    \nUnlikely to be dialysed. Dose as in
    \nnormal renal function
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nUnknown dialysability. Dose as in
    \nnormal renal function
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • Anti-arrhythmics: possibly increase\n

    concentration of amiodarone, flecainide,
    \nlidocaine and propafenone (increased
    \nrisk of ventricular arrhythmias) \u2013 avoid
    \nconcomitant use<\/p>\n

  • Antibacterials: concentration of both\n

    drugs increased with erythromycin;
    \nincreased concentration of rifabutin \u2013
    \nreduce rifabutin dose; concentration
    \nsignificantly reduced by rifampicin \u2013 avoid
    \nconcomitant use; possibly increased
    \ndapsone concentration; avoid concomitant
    \nuse with telithromycin in severe renal and
    \nhepatic impairment<\/p>\n

  • Antidepressants: concentration reduced\n

    by St John\u2019s wort \u2013 avoid concomitant use;
    \npossibly increased side effects of tricyclics;
    \npossibly reduced paroxetine concentration<\/p>\n

  • Antimalarials: avoid concomitant\n

    administration with artemether\/
    \nlumefantrine<\/p>\n

  • Antipsychotics: possibly inhibit\n

    aripiprazole metabolism \u2013 reduce
    \naripiprazole dose; possibly increased
    \nclozapine concentration; increased
    \npimozide and sertindole concentration
    \n(increased risk of ventricular arrhythmias)
    \n\u2013 avoid concomitant use<\/p>\n

  • Antivirals: concentration reduced by\n

    efavirenz, lopinavir and tipranavir;
    \nconcentration possibly reduced by
    \nnevirapine; concentration increased by
    \nritonavir<\/p>\n

  • Anxiolytics and hypnotics: increased risk\n

    of prolonged sedation and respiratory
    \ndepression with alprazolam, clonazepam,
    \ndiazepam, flurazepam and midazolam<\/p>\n

  • Cilostazol: possibly increased cilostazol\n

    concentration \u2013 avoid concomitant use
    \nErgot alkaloids: increased risk of ergotism <\/p>\n

    \u2013 avoid concomitant use. <\/p>\n

  • Immunosuppressants: monitor\n

    ciclosporin, tacrolimus and sirolimus
    \nlevels
    \nStatins: possibly increased risk of <\/p>\n

    myopathy with atorvastatin; possibly
    \nincreased myopathy with simvastatin \u2013
    \navoid concomitant use
    \nt is not licensed for use by anyone else.
    \n54 AMPrEnAVir<\/p>\n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nOral<\/p>\n

    Rate of Administration <\/H4>
    \n\u2013
    \n

    Comments<\/H4>
    \n\u2013
    \n

    OTHER INFORMATION <\/H4><\/p>\n
  • Oral solution contains vitamin E 46 units\/\n

    mL, potassium 26 micromol\/mL and
    \nsodium 174 micromol\/mL<\/p>\n

  • Avoid oral solution in renal impairment\n

    due to possible accumulation of propylene
    \nglycol<\/p>\n

  • Bioavailability of oral solution is 14\u201319%\n

    less than the capsules<\/p>\n","protected":false},"excerpt":{"rendered":"

    Amprenavir CLINICAL USE Protease inhibitor: HIV infection, in combination with<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3690","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3690"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3690\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}